TY - JOUR
T1 - Real world data on histological transformation in patients with follicular lymphoma
T2 - incidence, clinico-pathological risk factors and outcome in a nationwide Danish cohort
AU - Madsen, Charlotte
AU - Plesner, Trine Lindhardt
AU - Bentzen, Hans Herluf
AU - Jørgensen, Judit
AU - Sillesen, Ida Blok
AU - Himmelstrup, Bodil M.
AU - Josefsson, Pär
AU - Plesner, Torben
AU - Bennedsen, Tine Litske
AU - Ludvigsen, Maja
AU - d’Amore, Francesco A.
PY - 2020/11
Y1 - 2020/11
N2 - We investigated incidence, risk factors and outcome for follicular lymphoma (FL) patients with histologic transformation (HT) found at primary diagnosis (discordant/composite, dc-tFL) or sequentially (s-tFL). Between 2000 and 2015, 2773 patients were identified. The majority of patients (2252, 81%) did not experience HT (nt-FL), while 224 (8%) had dc-tFL and 297 (11%) s-tFL. The risk of HT was 2.2% per year and 9.6% at 5 years. Age ≥60, a high FLIPI risk score and LDH-elevation were associated with increased risk of HT. Calculated from primary diagnosis and compared with nt-FL, 5-year overall survival (OS) was inferior in both s-tFL and dc-tFL (nt-FL: 82%, s-tFL: 68%, dc-tFL: 68%; p =.001), whereas 5-year progression-free survival (PFS) was worse only in s-tFL (s-tFL: 18%, dc-tFL: 58%, nt-FL: 60%). Calculated from time of HT, s-tFL had inferior outcome compared to dc-tFL for both OS (s-tFL: 47%, dc-tFL: 68%, p =.001) and PFS (s-tFL: 35%, dc-tFL: 58%, p =.001).
AB - We investigated incidence, risk factors and outcome for follicular lymphoma (FL) patients with histologic transformation (HT) found at primary diagnosis (discordant/composite, dc-tFL) or sequentially (s-tFL). Between 2000 and 2015, 2773 patients were identified. The majority of patients (2252, 81%) did not experience HT (nt-FL), while 224 (8%) had dc-tFL and 297 (11%) s-tFL. The risk of HT was 2.2% per year and 9.6% at 5 years. Age ≥60, a high FLIPI risk score and LDH-elevation were associated with increased risk of HT. Calculated from primary diagnosis and compared with nt-FL, 5-year overall survival (OS) was inferior in both s-tFL and dc-tFL (nt-FL: 82%, s-tFL: 68%, dc-tFL: 68%; p =.001), whereas 5-year progression-free survival (PFS) was worse only in s-tFL (s-tFL: 18%, dc-tFL: 58%, nt-FL: 60%). Calculated from time of HT, s-tFL had inferior outcome compared to dc-tFL for both OS (s-tFL: 47%, dc-tFL: 68%, p =.001) and PFS (s-tFL: 35%, dc-tFL: 58%, p =.001).
KW - follicular lymphoma
KW - Rituximab era
KW - transformation
U2 - 10.1080/10428194.2020.1779254
DO - 10.1080/10428194.2020.1779254
M3 - Journal article
C2 - 33167719
AN - SCOPUS:85087040675
SN - 1042-8194
VL - 61
SP - 2584
EP - 2594
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 11
ER -